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Available pharmacological migraine treatments have 
incomplete efficacy and many of them may have intolerable 
adverse effects. There is thus a need for alternative, more 
efficient and better tolerable therapies. Pericranial nerve 
stimulation methods represent such an alternative. Methods 
using implantable electrodes and stimulators can be used in 
the most severely disabled patients due their invasive nature 
and high adverse event rate. Thanks to technological 
advances, non-invasive, user-friendly, transcutaneous 
stimulators have been developed recently and are applicable 
also in less disabled patients. In particular, supraorbital 
external trigeminal nerve stimulation (eTNS) with the Cefaly
® 
device was found effective for migraine prevention in a 
randomized, sham-controlled trial, two open studies and one 
post-market survey. Non-controlled pilot studies and an 
Internet survey suggest that the device is also useful for 
migraine attack treatment; the results of a sham-controlled 
trial are about to be published.  
The mode of action of eTNS in migraine is not fully 
understood. Like extra-cephalic transcutaneous electrical 
nerve stimulation (TENS), eTNS may have segmental “gate 
control” mechanisms as well as supra-segmental actions. 
Scarce evidence for a segmental mechanism comes from a 
pilot study of 10 patients in whom amplitude of the 
nociceptive blink reflex (nBR) was transiently reduced after 
one 20-min eTNS session. In healthy subjects, 1Hz noxious 
stimulation of the supra-orbital nerve produces a long-lasting 
reduction of the nBR and homotopic pain perception, while 3 
Hz stimulation of the greater occipital nerve has no effect on 
the nBR. A single session of eTNS in migraine patients 
during an attack relieves pain transiently, but it has no effect 
on cerebral metabolism. Conversely, after several months of 
eTNS with the Cefaly
®
, there is an increase in metabolism 
assessed with FDP-PET in pre-treatment hypo-metabolic 
medial prefrontal cortical areas, including anterior cingulate 
cortex, while trigeminal noxious heat-induced fMRI BOLD 
hyper-activation of the latter normalises. These metabolic 
changes are accompanied by a significant decrease in monthly 
attack frequency in compliant patients.  
Taken together, available data suggest that mode and 
site of Cefaly
®’s action may differ between its acute and 
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preventive anti-migraine 
effects. While it may 
relieve headache during an 
attack by a segmental, 
somatic afferent-induced 
blockade of nociceptive 
trigeminovascular afferents 
in trigeminal nucleus 
caudalis, its preventive 
effect more likely depends on a slow modulatory supra-
segmental mechanism that normalises activity in cortical 
areas controlling pain and its behavioural aspects. The 
correlations between segmental or supra-segmental actions 
and therapeutic efficacy need to be further investigated.   
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Introduction 
Migraine management includes acute 
and preventive treatments. While acute 
treatments aim at interrupting an attack and 
restore normal function (1), preventive 
treatments have the disease-modifying 
objective of reducing attack frequency and 
severity (2). Currently, migraine is mostly 
managed with pharmacologic treatments. 
The most commonly used drugs to interrupt 
migraine attacks are analgesics, non-stero-
idal anti-inflammatory drugs (NSAIDs), and 
triptans (3). Effective preventive drugs incl-
ude beta-blockers without intrinsic sym-
pathicomimetic activity, calcium channel 
blockers, sartans and the anti-convulsants 
topiramate and valproate (4), as well as 
nutraceuticals like riboflavin and co-enzyme 
Q10 (5).  
Besides the latter, most preventive anti-
migraine drugs are associated with moderate 
to severe side effects, have contraindications 
and only partial efficacy leading frequently 
to dissatisfaction and discontinuation by the 
patients (6, 7, 8). Consequently, 80% of 
patients are willing to change their current 
medication for a treatment with similar 
efficacy but fewer side effects (9). Last but 
not least, in patients with frequent and/or 
prolonged migraine attacks, excessive 
consumption of acute anti-migraine drugs 
may lead to headache chronification, i.e., 
medication overuse headache, which 
worsens the patients’ condition (10) 
 
1. The Clinical Evidence  
The shortcomings of pharmacological 
migr-aine management underscore the need 
for better treatments and have created a 
niche for non-pharmacologic therapies such 
as neurostimulation. Peripheral nerve stimul-
ation (PNS) is not a novel approach to treat 
headaches (see 11 for review).  Percutaneous 
nerve stimulation was reported effective for 
the treatment of various headaches since the 
90s (12, 13). Occipital nerve stimulation 
(ONS) was beneficial for chronic migraine 
in sham-controlled trials, although the global 
effect size was modest (14, 15, 16). The 
combination of percutaneous ONS and 
supraorbital nerve stimulation (SNS) was 
claimed to have a better effect, but 
randomized controlled trials are lacking 
(17). The common drawback of these 
neurostimulation methods is that they are 
invasive and applicable only to the most 
disabled patients with frequent, severe and 
drug-refractory migraine (18).  
The development of non-invasive 
trans-cutaneous stimulators opened the 
neuro-stimulation field to all migraine 
patients without consideration of disability 
or drug-refractoriness (see 19 for a review). 
The first studies showing beneficial effects 
in various headache types were published as 
early as 1985 (20, 21, 22, 23), the single-
blinded placebo-controlled trial by Solomon 
and Guglielmo (20) being the most 
convincing.  
It took 2 decades before techno-
logical advances allowed developing a 
portable, user-friendly and more effective 
external trigeminal stimulator (eTNS), the 
Cefaly
®
 (Cefaly Technology sprl, Grâce-
Hollogne, Belgium). The Cefaly® device 
stimulates transcutaneously supraorbital 
branches of the ophthalmic nerve and in the 
randomised, sham-controlled, blinded 
PREMICE trial (24), effective stimulation 
(pulse width 250μs, 60Hz stimulation 
frequency, 16mA intensity, 20-min daily 
application) was found clearly superior to 
sham stimulation (pulse width 30μs, 1Hz 
frequency, 1mA intensity) for the prevention 
of episodic migraine. After 3 months of 
treatment, mean number of monthly 
migraine days was significantly decreased 
and 38.1% of the 34 effectively treated 
patients had a ≥ 50% reduction in migraine 
days compared to 12.1% in the 33 sham-
treated patients. There were no adverse 
events. For comparison, in the pooled 
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analysis of topiramate RCTs, the 50% 
responder rate was 45.3%, but 50% of 
patients had drug-related side effects and 1 
out of 4 patients abandoned treatment 
because of intolerable adverse effects (25). 
As a consequence of the PREMICE trial, in 
March 2014 Cefaly
®
 was the first medical 
device approved by the FDA for the 
prevention of migraine. Its beneficial 
preventive effect in low-frequency migraine 
was also suggested by a small open study in 
24 drug-naive migraineurs (26) and a 
prospective registry involving 2,313 patients 
showed that eTNS is a well tolerated and 
safe therapy with mild adverse events 
reported by only 4.3% of patients (27).  
Although in clinical practice many 
patients report using Cefaly® during 
migraine attacks with a beneficial effect on 
headache and disability, only limited 
evidence is available for its efficiency in 
acute migraine treatment published in 
abstracts. In a pilot trial of 10 episodic 
migraine patients who treated 3 successive 
attacks with the device, total relief without 
rescue medication was obtained in 12% of 
attacks at 30 minutes, incomplete relief with 
rescue medication in 42.5% and no effect in 
45.5% (28).  In an open study of 16 patients, 
the Cefaly
®
 device was effective and well-
tolerated as rescue therapy for migraine 
attack symptoms present since at least 72 
hours; it reduced the migraine headache on 
average by 46%, and 56% of patients 
declared they would like to use the device 
again (29). In another open study, Chou et 
al. (30) treated 30 patients during an attack 
in the hospital for 1 hour, which resulted on 
average in a 57% decrease of headache 
intensity. The sham-controlled trial with a 
similar protocol is about to be completed 
(see table 1). We recently published the 
results of an Internet survey on migraine 
attack treatment with the Cefaly
® 
in 463 
regular users using a structured 
questionnaire: 88.6% of them reported using 
the device in 71.8% of their attacks; the use 
of the device allowed a reduction of acute 
medication intake in 42.6% of attacks (31).  
The precise mode of action of pericranial 
nerve neurostimulation methods in migraine 
remains to be determined. Recent 
neuroimaging studies, however, may shed 









10 episodic MO 
patients 
-1.3 reduction in monthly 
attack frequency 
5/10 patients satisfied 







67 episodic MO 
patients (34 verum, 
33 sham) 
≥ 50% responder rate 
Verum: 38.1% 
Sham: 12.1% 








≥ 50% responder rate: 
81% 
Russo et al. 







testing the Cefaly® 
 
54.4% satisfied & willing 
to buy after a 58-day test 
4.4% report adverse 
events (2.03%: local 
intolerance) 
Magis et al. 
J Head Pain 2013 
(27) 
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10 episodic MO 
patients 
3 attacks 
Attack outcome at 30 
min: 
12% - total relief 
45% - partial relief 
43% - no effect 




Rescue for attacks 
of  ≥ 72 h 
16 episodic MO 
patients 
46% reduction of 
headache 








Attack duration ≥ 3h 
30 episodic MO 
patients 
At 1 hour: 
57% reduction in head 
pain 
77% of patients with 
50% pain relief 












88.6% use the device in 
71.8% of attacks 
42.6% device-treated 
attacks with reduction of 
acute migraine drugs 
Penning & 
Schoenen 













Table 1: Synopsis of published and on-going clinical studies of external trigeminal nerve 




in migraine. MO: migraine without aura. Italics: on-going 
trials.  
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2. Possible Mechanisms of Action  
The initial rationale for the use of 
pericranial nerve stimulation in migraine 
postulated that convergence of somatic 
afferents from the trigeminal or the C2 
territories with visceral trigeminovascular 
afferents on spinal trigeminal nucleus 2
nd
 
order nociceptors might block ascending 
impulses in the pain pathway. Like 
transcutaneous electrical nerve stimulation 
(TENS) known to relieve neuropathic pain 
since many years (32), it was thought that 
peripheral nerve stimulation could block 
nociceptive activity at the segmental level 
via activation of large Aβ afferents 
according to Melzack & Wall’s gate control 
theory (33, 34). While this might be true for 
conventional low intensity-high frequency 
TENS, acupuncture-like high intensity-low 
frequency TENS and high intensity-high 
frequency TENS, resembling the Cefaly
® 
stimulation pattern, are more likely to 
engage extrasegmental mechanisms like 
activation of subcortical pain control centres 
(35). We will successively examine the 
evidence for a segmental and a supra-
segmental mode of action of eTNS in 
migraine therapy.  
 
2.1. Peripheral mechanisms 
The stimuli generated by eTNS 
generate nerve impulses that can in theory 
collide with noxious orthodromic afferent 
signals and extinguish them. This is more 
likely when Aδ fibers are activated by high 
intensity stimulation. Such a mechanism 
cannot play a significant role in migraine 
where somatic nociceptive afferents of the 
ophthalmic nerve are not supposed to be 
involved in headache generation, contrary to 
the visceral afferents of the 
trigeminovascular system. It was found 
recently, however, that branches of 
meningeal nociceptive fibers emerge at the 
level of cranial emissary canals and fissures 
to innervate extracranial structures like 
periosteum and muscles (36). These fibers 
have been described in the temporal, parietal 
and occipital areas and originate from the 
mandibulary and maxillary portions of the 
trigeminal ganglion, not from the 
ophthalmic division. Due to the anatomical 
position and the small surface of its 
supraorbital electrode, the Cefaly
®
 device is 
unlikely to activate significant numbers of 
these extracranial meningeal afferents. 
High intensity-low frequency TENS 
over muscles produces strong but 
comfortable muscle contraction that can 
activate muscle afferents to elicit analgesia 
(35). Interestingly, quantitative electro-
myography (EMG) recordings in 23 chronic 
migraine patients during eTNS with the 
Cefaly
®
 showed an increase of median 
frequency and amplitude of the myo-
electrical signal in anterior temporalis, 
auricularis posterior, and middle trapezius 
muscles, but not in frontalis (37). The 
significance of this finding for the mode of 
action of the device is doubtful, the more so 
that it is unlikely that pericranial muscle 
activity plays a pathogenic role in chronic 
migraine (38). 
 
2.2. Segmental mechanisms 
The hypothesis that pericranial nerve 
stimulation would be able to decrease 
trigeminal nociception by a segmental 
mechanism comparable to the gate control 
theory was not confirmed in several 
experimental studies. In rats, stimulation of 
the greater occipital nerve increased central 
excitability of 2
nd
 order nociceptors 
activated by dural afferents in the trigemino-
cervical complex (39). In humans, low 
frequency (3Hz) nociceptive stimulation of 
the greater occipital nerve had no effect on 
amplitude of the nociceptive blink reflex 
(nBR), a surrogate marker of spinal 
trigeminal nucleus excitability (40). By 
contrast, 1Hz noxious stimulation of the 
supra-orbital skin induced a long-lasting 
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depression of nBR amplitude and homotopic 
pain ratings in normal subjects, which was 
thought to be due to long term depression of 
2
nd
 order nociceptors in the spinal trigeminal 
nucleus (41). In an accompanying editorial, 
Cruccu and Truini (42) suggest that low 
frequency-high intensity acupuncture-like 
electrical stimulation could be a great 
opportunity in pain therapy, because it might 
attenuate the long-term potentiation of 
dorsal horn nociceptive synapses that 
contribute to hyperalgesia and allodynia.  
Unlike Aymanns et al.’s study (41), 
eTNS with Cefaly
® 
uses high frequency 
stimulation. Nonetheless, in the 
abovementioned pilot study (28), we tested 
the effect of one 20 min session of 
stimulation with the device (60Hz, 16mA) 
on amplitude and habituation of the nBR in 
10 migraineurs. Immediately after the 
stimulation, there was a mild, but significant 
decrease of nBR amplitude and a more 
pronounced decrease of habituation (Fig. 1)     
 
                       
Figure 1: nBR changes after one 20 min session with the Cefaly
®
 (60Hz, 16mA) (set-up and an 
illustrative recording on the left). Upper right: histogram of changes in area under the curve 
(AUC-average of 5 rectified responses) immediately after and 1h after the eTNS session. Lower 
right: histogram of change in AUC over 3 successive blocks of 5 averaged responses before and 
after eTNS. 
 
In another group of 15 migraine 
without aura patients between attacks, we 
also recorded contact heat-evoked potentials 
(CHEPs), a thermonociceptive cortical 
evoked response, before and after a single 
session with the Cefaly
®
. As shown in 
Figure 2, eTNS significantly decreased the 
amplitude of the CHEP obtained by a heat 
stimulus to the frontal skin, but not that of 
the CHEP elicited by stimulation at the 
wrist. The eTNS-induced decrease of the 
thermonociceptive potential is thus 
homotopic, suggesting that eTNS modulates 
nociception via trigemino-specific segmental 
or supra-segmental pathways. In view of the 
greater effect on CHEP than on nBR, a 
supra-segmental mechanism seems more 
likely.  
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Figure 2: Contact heat-evoked potential (CHEP) recorded over the scalp after heat stimulation at 
the front or at the wrist in 15 migraine without aura patients. Upper panel: illustrative recording 
of 5 averaged responses in one patient. Lower panels: amplitude of the 1
st
 block of 5 responses 
before and immediately after one 20 min session of eTNS (left: heat stimulation of the front; 
right: heat stimulation at the wrist.  
 
2.3. Supra-segmental mechanisms 
The 1
st
 indication for a central effect 
of the Cefaly
® 
came from a double-blinded, 
cross-over, sham-controlled trial in 30 
healthy volunteers that assessed its effects 
on psychomotor tests (43). This study found 
that reaction time in a psychomotor 
vigilance task and score on the Fatigue 
Visual Numeric Scale were significantly 
increased after one 20 min session of eTNS 
at 120Hz, while critical flicker fusion 
frequency was decreased, which suggested 
that the device had produced a mild, 
transient sedative effect. Whether such an 
effect contributes to the therapeutic benefit 
of Cefaly
®
 is uncertain, the more so that in 
clinical practice the highest stimulation 
frequency used is 100Hz, the protocol 
recommended for attack treatment.   
 
 
We have recently published the 
results of a fluoro-deoxyglucose (FDG)-PET 
study that analysed brain metabolism in 14 
patients suffering from episodic migraine 
without aura before, immediately after one 
20-min session and after a 3-months 
treatment period of daily 20-min sessions of 
supraorbital eTNS with the Cefaly
® 
(60Hz, 
16mA) (44). Baseline FDG-PET revealed a 
significant hypometabolism of orbitofrontal 
(OFC), rostral anterior cingulate cortices 
(rACC) and middle temporal lobe, compared 
to a control group of healthy volunteers. 
There was no significant metabolic change 
after one session of eTNS. By contrast, after 
3 months of daily stimulation, frequency of 
monthly migraine days significantly 
decreased in 10 compliant patients who 
performed at least 30% of the 90 
recommended sessions. An in-built software 
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that records number of sessions and time of 
use monitored compliance. In these patients 
the OFC and rACC hypometabolism was 
significantly reduced after 3 months (Fig. 3).  
 
      
Figure 3: Histogram of changes in monthly migraine attack frequency before and after 1, 2 and 3 
months of Cefaly
® 
treatment in 10 out of 14 compliant migraine without aura (MO) patients. 
Brain areas with a significantly different glucose uptake overlaid over an MRI anatomical map: 
hypometabolic areas in MO before treatment compared to 14 healthy volunteers (HV) (left 
panel); areas with increased metabolism after treatment in 10 compliant MO patients (right 
panel). In the middle: schematic representation of brain areas belonging to the pain/salience 
matrix after May 2009. rACC: rostral anterior cingulate cortex. pFWE: p corrected for multiple 
comparisons (family wise error corrected) (modified after 44). 
 
The change in OFC/rACC metabolism 
and the progressive reduction of migraine 
attack frequency with eTNS might suggest 
that the treatment exerts a slow central 
neuromodulatory effect, akin other 
peripheral nerve stimulations (see 45 for a 
review). Interestingly, Russo et al. (46) have 
reported in the perigenual part of the ACC 
greater fMRI BOLD activation after 
trigeminal noxious heat stimulation in 
migraine patients than in healthy volunteers. 
In a follow-up study, the same authors (47) 
found that this noxious heat-induced BOLD 
activation was significantly reduced after 2-
month eTNS with the Cefaly
® 
in 16 MO 
patients (Fig. 4).     
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Figure 4: Significantly different BOLD-response between MwA patients before eTNS treatment 
and HC and between MwA patients before and after eTNS treatment. A) T-map of statistically 
significant differences between groups overlaid onto a Talairach transformed Colin-27 T1 high-
resolution anatomical template; B) Bar graphs of percent BOLD signal changes at Talairach 
coordinates (x, y, z): right ACC= 12, 35, 7 during noxious trigeminal heat stimulation at 51° C in 
MwA patients before and after eTNS treatment and the HC group. C) Scatterplot showing 
significant correlations between ACC BOLD response to noxious heat before eTNS (y-axis) and 
the modification of the heat-induced ACC BOLD response after eTNS (i.e. the “delta value”) (x-
axis). D) Scatterplot showing significant correlations between modifications of the heat-induced 
ACC BOLD response changes after eTNS (x-axis) and post-treatment migraine attack 
frequency/month (y-axis) MwA: migraine without aura. HC: healthy controls (modified after 
47). 
 
Functional neuroimaging studies in 
chronic cluster headache (48) and chronic 
migraine patients (49) have shown that 
percutaneous occipital nerve stimulation is 
able to increase metabolism in central areas 
belonging to descending pain control 
centres, including the ACC, but leave 
unchanged disease-specific structures like 
the hypothalamus in cluster headache or the 
dorsal pons in migraine. By the same token, 
long electrical stimulations of the trigeminal 
ganglion in patients with trigeminal 
neuropathic pain increased regional blood 
flow in the ACC, OFC and medial frontal 
cortices, which was correlated with pain 
relief (50). Finally, opioid and placebo 
analgesia are also associated with increased 
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activity of OFC and rACC, suggesting a 
common underlying mechanism (51).  
A last piece of experimental 
evidence arguing in favour of a supra-
segmental action of eTNS comes from a 
study by Di Lenola et al. (52). These authors 
measured in migraine patients between 
attacks the effect of one 20 min session with 
Cefaly
®
 of high frequency oscillations 
(HFO) embedded in somato-sensory evoked 
cortical potentials, which reflect thalamo-
cortical activity and are decreased, 
indicating thalamo-cortical, in migraine 
(53). After eTNS, they found a significant 
increase in HFO. It remains, however, to be 
determined if there is a relation between this 
finding and the eTNS-induced changes in 
activity of medial frontal cortex areas.     
 
Conclusion 
Taken together, the above described 
studies suggest that eTNS with the Cefaly
® 
exerts its preventive anti-migraine action 
chiefly at supra-segmental levels, i.a. by 
modulating activity of medial frontal cortex 
areas involved in the control of the affective 
and cognitive dimensions of pain. These 
areas play indeed a paramount role in 
individual levels of central pain modulation 
in healthy subjects (54) and are 
dysfunctioning in chronic migraine (49), 
medication overuse headache (55) and 
chronic cluster headache (48). They are 
modulated both by transcutaneous and 
percutaneous pericranial nerve stimulation. 
The fact that involvement of medial frontal 
cortex areas seems not specific to migraine, 
nor limited to pain, and that eTNS can 
change thalamo-cortical circuits, may 
explain why pericranial neurostimulation, 
including eTNS, was reported to have also 
therapeutic effects in tension-type headache 
(56), fibromyalgia (57), depression (58) and 
epilepsy (59). 
Regarding the acute effects of eTNS 
during a migraine attack, the mechanism of 
action might be different. The preventive 
eTNS effect on migraine takes time and 
becomes maximal after 3 months in the 
PREMICE trial (24), which is compatible 
with slow modulation of central pain control 
centres. By contrast, the acute analgesic 
effect of Cefaly
®
 (30) and its inhibitory 
action on the nociceptive blink reflex during 
attacks (28) peak at 1h and tend to decrease 
thereafter, suggesting a transient inhibition 
of trigeminal nociception at the segmental 
level.  
The predominant mode and site of 
Cefaly
®’s action could thus differ between 
its acute effects, possibly exerted 
segmentally via somatic afferent-induced 
blockade of nociceptive trigeminovascular 
afferents, and its preventive effects, 
probably depending on activation of cortical 
areas controlling pain and its emotional 
aspects. Interestingly, the two mechanisms 
are intermingled in most Cefaly
®
-treated 
migraine patients, as they tend to use it both 
for prevention and for attack treatment. 
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